, Volume 32, Issue 6, pp 509–510 | Cite as

Das Merkelzellkarzinom

Sektion C


  1. 1.
    Poulsen M (2004) Merkel-cell carcinoma of the skin. Lancet Oncol 5(10):593–599CrossRefPubMedGoogle Scholar
  2. 2. – Das Portal für seltene Krankheiten und Orphan Drugs. Karzinom, kutanes neuroendokrines. Zugegriffen: 11. Oktober 2017
  3. 3.
    National Cancer Institute. Merkel Cell Carcinoma Treatment-Patient Version (PDQ®). Zugegriffen: 11. Oktober 2017
  4. 4.
    Duprat J et al (2011) A review of the epidemiology and treatment of Merkel cell carcinoma. Clinics 66(10):1817–1823CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Skin Cancer Foundation. Merkel Cell Carcinoma – What is Merkel Cell Carcinoma? Zugegriffen: 11. Oktober 2017
  6. 6.
    American Cancer Society. Signs and Symptoms of Merkel Cell Carcinoma. Zugegriffen: 11. Oktober 2017
  7. 7.
    Desch L et al (2013) Merkel Cell Carcinoma: Chemotherapy and Emerging New Therapeutic Options. J Skin Cancer. PubMedPubMedCentralGoogle Scholar
  8. 8.
    Hitchcock CL et al (1988) Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg 207:201–207CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Leong AS et al (1986) Criteria for the diagnosis of primary endocrine carcinoma of the skin (Merkel cell carcinoma); a histological, immunohistochemical and ultrastructural study of 13 cases. Pathology 18:393–399CrossRefPubMedGoogle Scholar
  10. 10.
    Becker J et al. S2k-Leitlinie 032/023: Merkelzellkarzinom. Stand: 03/2012.Google Scholar
  11. 11.
    Skin Cancer Foundation (2009) Zugegriffen: 11. Oktober 2017
  12. 12.
    Lemos B et al (2010) Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Derm 63(5):751–761CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Meland NB, Jackson IT (1986) Merkel cell tumor: diagnosis, prognosis, and management. Plast Reconstr Surg 77:632–638CrossRefPubMedGoogle Scholar
  14. 14.
    Assouline A et al (2011) Merkel cell carcinoma of skin-current controversies and recommendations. Rare Tumors 3(2):e23CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gonzalez RJ et al (2010) The surgical management of primary and metastatic Merkel cell carcinoma. Curr Probl Cancer 34:77–96CrossRefPubMedGoogle Scholar
  16. 16.
    Kukko H et al (2012) Merkel cell carcinoma - a population-based epidemiological study in Finland with a clinical series of 181 cases. Eur J Cancer 48(5):737–742CrossRefGoogle Scholar
  17. 17.
    Poulsen M et al (2010) Factors influencing relapse-free survival in Merkel cell carcinoma of the lower limb: a review of 60 cases. Int J Radiat Oncol Biol Phys 76(2):393–397CrossRefPubMedGoogle Scholar
  18. 18.
    National Comprehensive Cancer Network (2016) Merkel Cell Carcinoma Guidelines version I. Zugegriffen: 11. Oktober 2017Google Scholar
  19. 19.
    Henness S et al (2008) Management of Merkel tumours: an evidence-based review. Curr Opin Oncol 20:280–286CrossRefPubMedGoogle Scholar
  20. 20.
    Rabinowits G (2014) Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon? Cancers (Basel) 6(2):1180–1194CrossRefGoogle Scholar
  21. 21.
    Triozzi PL et al (2013) The role of the immune response in merkel cell carcinoma. Cancers (Basel) 5(1):234–254CrossRefGoogle Scholar
  22. 22.
    Jouary T et al (2012) Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol 23(4):1074–1080CrossRefPubMedGoogle Scholar
  23. 23.
    Iyer JG et al (2016) Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 5(9):2294–2301CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Voog E et al (1999) Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85(12):2589–2595CrossRefPubMedGoogle Scholar
  25. 25.
    Kaufman HL et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10):1374–1385CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Personalised recommendations